MedTrace Logo

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

NCT03252340 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2023-02-15

No results posted yet for this study

Summary

This study aims to evaluate safety in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of ADSTEM Inj. Since this is an observational study of patients participated in Phase 1 clinical trials, no drug is administered in this study.

Conditions

Interventions

DRUG

ADSTEM Inj.

1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial. 2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.

Sponsors & Collaborators

  • EHL Bio Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Young-joon Seo, M.D, Ph.D · Chungnam National University Hospital

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-19
Primary Completion
2022-08-17
Completion
2022-09-27

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03252340 on ClinicalTrials.gov